Most Affordable Compounded Semaglutide Online: Price Comparison of GLP-1 Telehealth Providers
⚠ Prototype dataset — prices consolidated from public provider pages and flagged for re-verification before publishing.
The cheapest verified compounded semaglutide in June 2026 is Embody at $99/month, on a flat rate that doesn't rise as your dose increases. bmiMD ($139), NexLife ($145, flat), and Novi ($149) follow. Compounded semaglutide is generally a little cheaper than compounded tirzepatide. For the lowest cost at a maintenance dose among fully credentialed providers (LegitScript + dual 503A/503B + included labs + flat pricing), NexLife at $145/month is the only option that checks every box.
Key takeaways
- Lowest sticker price: Embody, $99/mo flat.
- Lowest fully-credentialed price: NexLife, $145/mo flat across the full 0.25–2.4 mg titration.
- Cheaper than tirzepatide: compounded semaglutide runs ~$99–$299 vs. ~$99–$329 for tirzepatide.
- Brand context: retail Wegovy lists near $1,349/mo — compounded is 80–90% cheaper for the same molecule.
- More than weight loss: the SELECT trial showed semaglutide cut major cardiovascular events by ~20%.
01 · The recordCheapest verified compounded semaglutide, ranked by price
Every provider below dispenses through a US-licensed 503A pharmacy or 503B outsourcing facility with a named prescriber. The table is sortable. "True / mo" is the price at a typical maintenance dose — what actually hits your card after titration.
Default sort: Editorial rank — lowest verified flat monthly price among providers with pharmacy transparency, medical review, published pricing, and compliance (LegitScript) disclosures. ✓ = passes all rubric criteria. Click any column to re-sort (e.g. by raw advertised price).
| Rank | Provider ↕ | Advertised ↕ | True / mo ↕ | 12-mo ↕ | Rubric ↕ | Credentials |
|---|
Sources: consolidated provider pricing pages, verified Jun 2026. Flat = price held across full 0.25–2.4 mg titration. 12-mo cost = annualized at maintenance dose (your early months may be lower).
02 · The catchWhy the cheapest sticker price isn't the cheapest year
The "from $X" price you see is almost always the starter dose — 0.25 mg for semaglutide. Most people titrate up over several months, and at many providers the price rises with the dose. A program that opens at $99 and settles at $199 costs more over a year than a flat $145 program. Here are all 15 providers ranked by 12-month cost at a maintenance dose.
12-month cost at maintenance dose
Annualized. Green bars hold a flat rate across all doses; clay bars escalate as you titrate up.
03 · Best credentialed valueThe lowest price that clears every credential check
Embody is the lowest price, but it runs a lighter clinical wrap with no included labs. Among providers that pass every credential check we track, the same rare combination applies as on the tirzepatide side: flat dose-independent pricing and dual 503A/503B disclosure and included lab review and LegitScript certification. In our current dataset, only NexLife carries all four — and its semaglutide rate is lower than its tirzepatide rate.
NexLife
★★★★★ Compounded semaglutide- MD/DO-supervised care
- 503A & 503B pharmacy network
- Labs included
- LegitScript-certified
- NABP-accredited pharmacy partners
- Flat rate, dose-independent
- Third-party batch testing
- Care360 coaching included
Editorial selection by our published rubric. We are not paid by NexLife and earn no commission from this link — see how this site works.
04 · ContextHow compounded compares to brand Wegovy & Ozempic
Compounded semaglutide contains the same active ingredient as Novo Nordisk's Wegovy (weight management) and Ozempic (type 2 diabetes). The difference is the regulatory path and the price.
Same molecule, four prices
Monthly cost by route to patient, June 2026. Compounded telehealth is roughly 85% below brand retail.
Brand-name Wegovy lists near $1,349/month at retail, Ozempic around $969. Novo's self-pay program (NovoCare) runs about $499. Compounded semaglutide via telehealth runs $99–$299 — the lowest legal route to the molecule for an uninsured patient.
05 · The choiceSemaglutide or tirzepatide — which should you compound?
Both are legitimate, and the right answer depends on your goals, tolerance, and budget. Tirzepatide tends to produce more weight loss; semaglutide is usually a bit cheaper and has the deeper cardiovascular-outcomes evidence base. In SURPASS-2, tirzepatide produced about 47% more weight loss than semaglutide 1 mg in type 2 diabetes. If your priority is maximum weight loss, tirzepatide leads; if it's cost or proven heart-health benefit, semaglutide is compelling. See our full breakdown: semaglutide vs tirzepatide and the cheapest compounded tirzepatide ranking.
06 · EvidenceDoes compounded semaglutide actually work?
The active ingredient is identical to the molecule studied in Novo Nordisk's pivotal trials. Beyond weight loss, semaglutide has the strongest cardiovascular-outcomes data of any GLP-1 medication. There are no Phase 3 trials of compounded formulations specifically — the honest caveat — but the molecule's record is robust.
The SELECT trial is the differentiator: in adults with established cardiovascular disease and overweight or obesity without diabetes, semaglutide reduced the risk of cardiovascular death, heart attack, or stroke by about 20% over roughly three years. Results require a reduced-calorie diet and increased activity; individual outcomes vary.
07 · How we rankOur methodology — and who pays us
Providers are scored on six fixed pillars applied identically to every program: true-price transparency (25%), pharmacy traceability (20%), prescriber model (20%), regulatory posture (15%), what's included (10%), and plan terms (10%). When sources disagree on a price, we flag the entry rather than pick the friendlier number. Full detail on our methodology page.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →